DAB389IL-2 (Denileukin Diftitox, ONTAK): Other Potential Applications

Clinical Lymphoma

Volumn 1, Issue 1 SUPPL., 2000, Pages

  LeMaistre, C Frederick ^a  

^a TEXAS TRANSPLANT INSTITUTE   (United States)

Author keywords

Autoimmune disease; DAB389IL 2; Follicular lymphomas; Non Hodgkin's lymphoma; Transplantation

Indexed keywords

DENILEUKIN DIFTITOX; DIPHTHERIA TOXIN; HYBRID PROTEIN; IMMUNOSUPPRESSIVE AGENT; IMMUNOTOXIN; INTERLEUKIN 2;

AUTOIMMUNE DISEASE; CLINICAL TRIAL; CUTANEOUS T CELL LYMPHOMA; HUMAN; NONHODGKIN LYMPHOMA; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; SKIN TUMOR;

ARTHRITIS, RHEUMATOID; AUTOIMMUNE DISEASES; CLINICAL TRIALS; DIPHTHERIA TOXIN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTOXINS; INTERLEUKIN-2; LYMPHOMA, NON-HODGKIN; LYMPHOMA, T-CELL, CUTANEOUS; PSORIASIS; RECOMBINANT FUSION PROTEINS; SKIN NEOPLASMS;

EID: 0013259304     PISSN: 15269655     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2000.s.007     Document Type: Article

References (19)

1. 389IL-2) in lymphomas expressing the receptor for interleukin-2. Blood 1998; 91:399-405.
2. 389IL-2 (Ontak™) for the treatment of mycosis fungoides (MF). Blood 1997; 90:586a (Abstract #2607).
3. 486IL-2 in hematological cancers. Cancer Res 1993; 53:3930-3934.
4. 486IL-2 in advanced mycosis fungoides and the Sezary syndrome: correlation of activity and interleukin-2 receptor expression in a phase II study. Blood 1994; 84:1765-1774.
5. Fisher RI, Gaynor ER, Dahlberg S, et al. A phase III comparison of CHOP vs. m-BACOD vs. ProMACE-CytaBOM vs. MACOP-B in patients with intermediate-or high-grade non-Hodgkin's lymphoma: results of SWOG-8516 (Intergroup 0067), the National High-Priority Lymphoma Study. Ann Oncol 1994; 5:91-95.
6. Perentesis JP, Waddick KG, Bendel AE, et al. Induction of apoptosis in multidrug-resistant and radiation-resistant acute myeloid leukemia cells by a recombinant fusion toxin directed against the human granulocyte macrophage colony-stimulating factor receptor. Clin Cancer Res 1997; 3:347-355.
7. O'Connor R, Liu C, Ferris CA, et al. Anti-B4-blocked ricin synergizes with doxorubicin and etoposide on multidrug-resistant and drug-sensitive tumors. Blood 1995; 86:4286-4294.
8. Scadden DT, Schenkein DP, Bernstein Z, et al. Immunotoxin combined with chemotherapy for patients with AIDS-related non-Hodgkin's lymphoma. Cancer 1998; 83:2580-2587.
9. Cantrell DA, Smith KA. The interleukin-2 T-cell system: a new cell growth model. Science 1984; 224:1312-1316.
10. Kelley VE, Bacha P. Pankewycz O, et al. Interleukin 2-diphtheria toxin fusion protein can abolish cell-mediated immunity in vivo. Proc Natl Acad Sci USA 1988; 85:3980-3984.
11. Pankewycz O, Mackie J, Hassarjian R, et al. Imerleukin-2-diphtheria toxin fusion protein prolongs murine islet cell engraftment. Transplantation 1989; 47:318-322.
12. Kirkman RL, Bacha P, Barrett LV, et al. Prolongation of cardiac allograft survival in murine recipients treated with a diphtheria toxin-related interleukin-2 fusion protein. Transplantation 1989; 47:327-330.
13. Vincenti F, Kirkman R, Light S, et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. N Engl J Med 1998; 338:161-165.
14. Harris DT. Sakiestewa D, Lyons C, et al. Prevention of graft-versus-host disease (GVHD) by elimination of recipient-reactive donor T cells with recombinant toxins that target the interleukin 2 (IL-2) receptor. Bone Marrow Transplant 1999; 23:137-144.
15. 486IL-2) in refractory rheumatoid arthritis. A double-blind, placebo-controlled trial with open-label extension. Arthritis Rheum 1995; 38:1177-1186.
16. 389IL-2) selectively targets activated human peripheral blood and lamina propria lymphocytes. Dig Dis Sci 1997; 42:1542-1548.
17. 389IL-2 to patients with recalcitrant psoriasis: a double-blind, phase II multicenter trial. J Am Acad Dermatol 1998; 38:938-944.
18. Finberg RW, Wahl SM, Allen JB, et al. Selective elimination of HIV-1-infected cells with an interleukin-2 receptor-specific cytotoxin. Science 1991; 252:1703-1705.
19. 389IL-2. J Acquir Immune Defic Syndr 1992; 5:1181-1187.